Our Business Biocon Biologics Biocon biologics’ research and development organisation is fully integrated to develop high quality biosimilars (recombinant insulins, monoclonal antibodies and other protein therapeutics) that can be registered in highly regulated markets like the u.s., europe, canada, australia and japan. With a unique portfolio of monoclonal antibodies, recombinant proteins and insulins, biocon biologics is fully committed to the long term sustainability of global biosimilars access, investing more than $1 billion in r&d and global scale manufacturing over the last 2 decades.
Biocon Biologics Hiring In Research And Development Biocon biologics limited, a subsidiary of biocon limited, is a fully integrated global biosimilars organization. it is leveraging cutting edge science, innovative tech platforms and advanced. Biocon biologics’ research and development organisation is fully integrated to develop high quality biosimilars (recombinant insulins, monoclonal antibodies and other protein therapeutics) that can be registered in highly regulated markets like u.s., europe, canada, australia and japan. Biocon’s quest to develop affordable therapies and impact global healthcare led it to invest in developing novel biologics and novel targets in the area of large molecules, at a time when the pharma industry in india was focused on the safer business of manufacturing generic medicines. You are now leaving the biocon biologics corporate website for a biocon biologics eu corporate microsite that is solely responsible for its content, including its compliance with guidelines applicable in certain geographies.
Biocon Biologics A Blog By Biocon Biocon’s quest to develop affordable therapies and impact global healthcare led it to invest in developing novel biologics and novel targets in the area of large molecules, at a time when the pharma industry in india was focused on the safer business of manufacturing generic medicines. You are now leaving the biocon biologics corporate website for a biocon biologics eu corporate microsite that is solely responsible for its content, including its compliance with guidelines applicable in certain geographies. Our r&d team comprises 500 highly qualified scientists and post graduates from different streams of science and engineering that leverage our biotechnology and chemistry capabilities to develop highly complex and challenging molecules involving high end product and process characterisation. Biocon biologics is transforming patient outcomes by making life changing therapies more accessible to the world. through affordable biosimilars, we are reducing the global healthcare burden, increasing treatment options and driving innovation in biologics, to advance health equity, globally. Biocon’s discovery led r&d focuses on the entire drug research and development pathway. we aim to develop novel biopharmaceuticals. It is leveraging cutting edge science, innovative tech platforms and advanced research & development capabilities to lower treatment costs while improving healthcare outcomes.
Comments are closed.